Pfizer
Pfizer launches Healthcare Hub to support healthtech startups
April 19, 2017Medical Communications, Research and Development HealthTech, Pfizer, healthcare
Pfizer has announced the launch of ‘Pfizer Healthcare Hub: London’, a project that aims to help startups, focusing on the …
Old antibiotic nears new FDA approval after positive trials
April 7, 2017Medical Communications, Research and Development Pfizer, Zavante, Zolyd, antibiotic
Zavante, a biotech company based in San Diego, has unveiled positive results from a recent Phase II/III trials that could …
Pfizer resolves pension dispute at Irish facility
April 5, 2017Manufacturing and Production, Research and Development Ireland, Pfizer, Siptu
Pfizer and trade union Siptu have reached an agreement over a pension dispute at the company’s plant at Ringaskiddy in …
Pfizer secures expanded approval for Ibrance
April 3, 2017Sales and Marketing Pfizer, ibrance
Pfizer has announced that FDA has approved its supplemental New Drug Application (sNDA) for Ibrance, meaning that the drug is …
Pfizer receive European approval for arthritis drug
March 27, 2017Sales and Marketing Pfizer, rheumatoid arthritis
Following on from the positive opinion given to Xeljanz in January of this year, Pfizer’s drug has now been given …
Merck KGaA and Pfizer enter the immunotherapy market with Bavencio
March 27, 2017Sales and Marketing Bavencio, Merck KGaA, Pfizer
Merck KGaA and Pfizer have won approval for the fourth immunotherapy treatment to enter the market, with an indication in …
Advent reportedly backs out of bid for Pfizer’s Brazil plant
March 23, 2017Sales and Marketing Brazil, Pfizer, generics
It has been reported that Advent International Corp has pulled out of bidding for Pfizer’s stake in Brazilian generics manufacturer, …
Pfizer announces partnership with UK university
March 13, 2017Medical Communications, Sales and Marketing Pfizer, Swansea University
Pfizer and Swansea University have announced plans to collaborate on a new Innovation Hub at Swansea University’s new £450 million …
Pfizer plant receives FDA warning letter for contamination of medicine
March 1, 2017Manufacturing and Production Copaxone, Mylan, Pfizer, Teva, generics
The FDA has issued a warning letter to Pfizer after inspectors discovered that the plant did not protect properly against …
Pfizer’s Remicade biosimilar displays similar efficacy
February 22, 2017Research and Development Johnson & Johnson, Pfizer, Remicade, inflectra
Pfizer and Celltrion have announced new data for their Remicade biosimilar, Inflectra, that shows that the drug is comparable in …
FDA Priority Review for Pfizer investigational leukaemia drug
February 22, 2017Research and Development, Sales and Marketing EMA, FDA, Inotuzumab ozogamicin, Pfizer, priority review
Pfizer has announced that its leukaemia treatment inotuzumab ozogamicin has been accepted for Priority Review by the US Food and …
Pfizer and Flynn: How are ‘excessive’ prices for generic drugs possible and should competition authorities do more about exploitative pricing?
February 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, Pfizer, flynn
As last year came to a close, the headlines were rocked by the news that pharma giant Pfizer had been …
NICE rejects Pfizer’s first-in-class breast cancer drug
February 3, 2017Medical Communications, Sales and Marketing NICE, Pfizer, breast cancer
NICE has published draft guidelines which reject Pfizer’s Ibrance (palbociclib) based primarily on the cost of the drug but also …
Hospira in US-wide recall of product due to contamination
January 25, 2017Medical Communications Contamination, Hospira, Pfizer
Hospira, a company owned by Pfizer, has been forced to recall a batch of injectable drugs due to “the presence …
22 pharma companies join forces for global non-communicable disease initiative
January 18, 2017Research and Development BMS, Celgene, Eisai, Eli Lilly, GSK, J&J, JJ, MSD, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda
The World Economic Forum Annual Meeting in Switzerland has seen the launch of Access Accelerated, a global initiative consisting of …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
